This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Play TheStreet's FDA Drug-Approval Contest

BOSTON ( TheStreet) -- Welcome to TheStreet's first-ever FDA Drug Approval Predictions Contest.

Your challenge: Correctly predict the approval decisions to be made by the U.S. Food and Drug Administration on 11 new drugs in October. The lawyers (party poopers) won't let us offer a prize without official rules, contracts, etc., so the person(s) with the most accurate predictions will, instead, receive a hearty congratulations, a mention in a future column and bragging rights as the best FDA drug-approval prognosticator in all the land.

To simplify the contest, you have three outcomes to choose from for each drug approval decision:

1. Full Approval: The big win, meaning the drug is approved and can be marketed for sale immediately.

2. Complete Response Letter: FDA has some concerns or issues (incomplete data, labeling, risk management, etc.) that prevent the drug from being approved immediately. In other words, the drug's approval is delayed for some reason.

3. No Decision: FDA chooses to extend the drug's review time, i.e., pushes out the approval decision to a later date. With the FDA looking at an unprecedented number of approval decisions in such a short time period, it won't be surprising to see some of these drug approvals delayed.

The 11 drugs up for FDA approval are listed below in chronological order. Again, please use one of three choices for your prediction: Full Approval, Complete Response Letter or No Decision.

To play TheStreet's FDA Drug Approval Prediction Contest, please copy the drug list, write in your approval prediction, and post your predictions using the "Add Comment" button found at the top or bottom of this Web page. You'll need to complete a short registration to post a comment -- make sure you include a valid email address so we can contact the winners.

Entries received after the start of October are eligible for the contest, but you won't get credit for drug-approval decisions already made by the time your entry was received.

Good luck!

Pending FDA Drug Approval Decisions:

Oct. 1: Hospira's (HSP) Dyloject for acute moderate to severe pain in adults.

Oct. 4: Human Genome Sciences' (HGSI) Zalbin for hepatitis C.

Oct. 11: Alexza Pharmaceuticals' (ALXA - Get Report) AZ-004 for agitation in patients with schizophrenia or bipolar disorder.

Jazz Pharmaceuticals' (JAZZ - Get Report) JZP-6 for fibromyalgia.

Oct. 12: Alkermes' (ALKS - Get Report) Vivitrol for opioid addiction.

Oct 22: Arena Pharmaceuticals' (ARNA - Get Report) lorcaserin for obesity.

Amylin Pharmaceuticals (AMLN), Alkermes and Eli Lilly's (LLY) Bydureon for diabetes.

Oct. 28: Vivus' (VVUS) Qnexa for obesity.

Oct. 29: Avanir Pharmaceuticals' (AVNR) Zenvia for pseudobulbar affect.

Forest Labs (FRX) ceftaroline for Community Acquired Pneumonia. Oct. 30

Biodel's (BIOD) Linjeta for diabetes.

--Written by Adam Feuerstein in Boston.

To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HSP $0.00 0.00%
ALXA $0.64 6.68%
ALKS $41.29 1.77%
ARNA $1.77 -1.12%
JAZZ $152.00 -0.63%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs